Athira Pharma, Inc. (NASDAQ: ATHA), a prominent biopharmaceutical company specializing in neurodegenerative diseases, has announced the completion of patient dosing in the Phase 2/3 LIFT-AD clinical trial. This trial is pivotal in evaluating fosgonimeton, a novel treatment for individuals with mild-to-moderate Alzheimer’s disease (AD). Athira is set to unveil topline results by the end of […]
Zydus Lifesciences, a renowned global pharmaceutical company, has achieved a significant milestone by completing the enrollment for the Phase II clinical trial of its novel oral NLRP3 inflammasome inhibitor, Usnoflast (ZYIL1), aimed at treating patients with Amyotrophic Lateral Sclerosis (ALS). This development marks a pivotal step in addressing the urgent need for effective treatments in […]
